Friedman AS., et al. - Via an observational study of e‐cigarette or vaping product use‐associated lung injury (EVALI) data from US states’ health departments, researchers examined if either mass‐marketed nicotine e‐cigarettes or cannabis use drove the 2019 US outbreak of EVALI vs an additive in regionally available black‐market e‐liquids. Findings revealed an average state EVALI prevalence of 1.4 cases per 100,000 12–64‐year‐olds. A cluster of seven contiguous states in the northern Midwest showed a high‐prevalence. They observed negative association of EVALI cases per capita with rates of vaping and past‐month cannabis use. States with greater rates of e‐cigarette and cannabis use before the 2019 EVALI outbreak exhibited lower EVALI prevalence. Results thereby suggest that locally distributed e‐liquids or additives most prevalent in the affected areas, rather than e‐cigarette or cannabis use resulted in rise in EVALI cases.